Veracode Named a Leader in the Gartner® Magic Quadrant™ Application Security Testing for 11 th Consecutive Time
14.10.2025 18:48:00 EEST | Business Wire | Press release
Veracode, the global leader in application risk management, has once again been positioned as a Leader in the 2025 Gartner® Magic Quadrant™ for Application Security Testing (AST)¹. This marks the company’s 11th consecutive time as a Leader since the report was first published. The analysis represents one of the industry’s most in-depth and unbiased evaluations of market competitors.
“Over nearly two decades, Veracode has earned a reputation as a trusted partner for thousands of organizations worldwide,” said Derek Maki, Senior Vice President & Head of Product at Veracode. “From pioneering security integration into the software development lifecycle to redefining AI-powered application risk management, we’ve always been at the forefront of innovation. We believe our continued position as a Leader in the Gartner Magic Quadrant reflects our unwavering commitment to customer success and the meaningful impact we deliver to business leaders, developers, and security teams every day. As AI fundamentally transforms how software is built, we’re ensuring security evolves just as rapidly.”
Modern Software Security in a Unified Platform
The 2025 Gartner® Magic Quadrant™ for AST examines key themes shaping the application security landscape, including the need for secure software development across the entire software development lifecycle, managing vulnerabilities in complex supply chains, and the increasing focus on cloud-native applications. Veracode is evaluated for both Ability to Execute and Completeness of Vision.
Veracode is committed to holistic risk management, providing assurance, context, and continuity to customers with global support and dedicated success management. The company’s advanced AI-powered engine analyzes code in hundreds of languages to identify and resolve vulnerabilities at their core. Its unified Application Security Posture Management (ASPM) solution also provides root cause analysis to help prioritize and neutralize threats, minimizing risk and empowering teams to build securely from the start.
Advanced Protection for the Software Supply Chain
With 70 percent of critical security debt originating from third-party code and the software supply chain, enterprises are under enormous pressure to prevent, detect, and respond to cyber threats. Veracode has transformed itself into a comprehensive Application Risk Management (ARM) platform through strategic acquisitions, including Longbow Security in 2024 (now integrated as Veracode Risk Manager [VRM]) to provide application security posture management capabilities. The company further enhanced its software supply chain security capabilities through the acquisition of Phylum in 2025, adding real-time malicious package blocking and automated threat intelligence that stops supply chain attacks at the point of entry—before compromised code ever touches an organization’s environment.
“The reality is that modern applications are AI-assisted, API-connected, and assembled at unprecedented speed,” said Maki. “Our platform is built for this reality—not just yesterday's monolithic applications. With our recent acquisitions of Longbow and Phylum, we're not just scanning code anymore; we're providing real-time risk intelligence across the entire software supply chain. This means our customers can actually prevent malicious packages from entering their codebase, not just discover vulnerabilities after the fact. That's the difference between traditional AppSec and true application risk management.”
Today, Veracode offers a comprehensive suite of application security testing capabilities through its cloud-native ARM platform. These include Static Analysis Security Testing (SAST), Dynamic Analysis Security Testing (DAST), Software Composition Analysis (SCA), Package Firewall, container scanning, Infrastructure as Code (IaC) scanning, penetration testing as a service, application security program management support, remediation consulting, and security training for developers offered in both hands-on experiential and course-based formats.
Pioneering AI-Powered Security Innovation
Launched in 2023 as the first solution of its kind to combine AI and human insight, Veracode Fix generates automated fix suggestions, covering more than 70 percent of detected flaws across 10 supported programming languages. The tool enables developers to burn down accumulated security debt quickly and efficiently.
A Strong Vision for the Future
Continuous, integrated, and automated risk management is the bedrock of modern software security. Veracode has evolved its platform to address this critical requirement for security and development teams.
With a strong vision to lead the future of application risk management, Veracode remains committed to innovating and supporting customers’ expanding needs. The company will continue to invest in technology, resources, and talent to help create a trustworthy, transparent, and resilient digital infrastructure.
To learn more about Veracode’s platform evaluation, download a complimentary copy of the full 2025 Gartner® Magic Quadrant™ for Application Security Testing on Veracode’s website.
To understand more about AI-powered application risk management, please visit: https://www.veracode.com/products
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
¹ Gartner, Magic Quadrant for Application Security Testing, By Jason Gross, Mark Horvath, Giles Williams, Shailendra Upadhyay, Dionisio Zumerle, Aaron Lord, 6 October 2025
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, Malicious Package Detection, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.
Copyright © 2025 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251010276937/en/
Contacts
Press and Media:
Katy Gwilliam
Head of Global Communications, Veracode
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom